Merrimack Pharmaceuticals Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer

CAMBRIDGE, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that results of the successful Phase 3 NAPOLI-1 study in metastatic pancreatic cancer will be communicated in an oral presentation at the European Society for Medical Oncology 16 th World Congress on Gastrointestinal Cancer (ESMO GI) held from June 25th to 28th, 2014 at The International Convention Center of Barcelona in Barcelona, Spain. The data will be presented by Andrea Wang-Gillam, M.D., Ph.D., Assistant Professor of Medicine, Division of Oncology, Washington University School of Medicine, and the co-chair of the steering committee for the NAPOLI-1 study. The presentation will include additional efficacy and safety data from the three arm study of MM-398, a nanoliposomal irinotecan, in patients with metastatic pancreatic cancer who have received prior gemcitabine-based therapy.

"We are honored that the findings of MM-398 in combination with 5-fluorouracil and leucovorin in patients with post-gemcitabine pancreatic cancer from our NAPOLI-1 study have been accepted for oral presentation at ESMO GI," said Eliel Bayever, M.D., Vice President of Clinical Development at Merrimack. "We look forward to updating the medical oncology community with more comprehensive results of our study in treating this devastating disease. We are especially grateful to the patients, their families and caregivers, the investigators, and the research community for their commitment to this important study."

Oral Presentation:
  • NAPOLI-1: Randomized Phase 3 Study of MM-398 (nal-IRI), with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-based Therapy (Abstract #O-0003) Session II: Cancer of the pancreas and bile ducts Wednesday, June 25, 2014, 5:00 p.m. CEST Poster viewing time: Thursday, June 26, 2014, 10:30-11:00 a.m. and 4:30-5:00 p.m. CEST CCIB, Exhibit Hall

Merrimack to Host Conference Call

Merrimack will host an investor conference call and webcast at 8 a.m., Eastern Time, on Thursday, June 26, 2014 where Dr. Wang-Gillam will review the data presented at ESMO GI. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 61076181.

If you liked this article you might like

Verastem Shares Are Exploding 50% -- Here's Why

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Trevena, Synergy Lead Biotech Movers

These 5 Stocks Under $10 Could Explode Up Soon